Key facts
- This page summarizes Dov A. Goldstein MD's Form 4 filing for Gain Therapeutics, Inc. (GANX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jul 2026, 08:33.
Dov A. Goldstein MD - 15 Jul 2026 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)
- Reporting relationship
- Director
- Issuer ticker
- GANX
- Reported as of
- 15 Jul 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jul 2026, 08:33:09 UTC
- Prior SEC filing
- 24 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dov A. Goldstein
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Dov A. Goldstein MD filed Form 4 for Gain Therapeutics, Inc. (GANX) on 17 Jul 2026.
Change
- Previous filing in this sequence was filed on 24 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001120478
Primary reporting owner
GOLDSTEIN DOV A MD
- Relationship
- Director
- Address
- C/O GAIN THERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 220, BETHESDA
- Signature
- /s/ Dov A. Goldstein
- Signature date
- 17 Jul 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GANX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +25,000
- Change %
- Price
- $0.000000*
- Shares after
- 25,000
- Date
- 15 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $1.68
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.